Intracerebral Hemorrhage
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Intracerebral Hemorrhage is a moderately active landscape with 68 programs across 27 companies. The most active players are Triax, Cumberland Pharmaceuticals, Shanghai IxCell Biotechnology Co., LTD. 10 therapies are approved with 8 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
98%
Small molecule
81 of 83 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 83 classified programs, each share of the total. Modality classified for 99% of 89 pipeline programs.
Analysis
Trial Status
94
clinical trials
Clinical Trials
Trial Activity
94 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)